Peptide Stack

Tesamorelin + Ipamorelin

Tesa/IPA · tesamorelin ipamorelin blend

Clinic-style blend pairing FDA-approved tesamorelin (Egrifta, GHRH analog for HIV-associated lipodystrophy) with ipamorelin. Sold as one reconstituted vial on some research/clinic menus. Tesamorelin remains a prescription drug; stacking it with a research GHRP is off-label and not a labeled indication.

Not FDA-approved - research chemicalWADA (S2) - prohibited in sport at all times

Quick answer

What it is: Clinic-style blend pairing FDA-approved tesamorelin (Egrifta, GHRH analog for HIV-associated lipodystrophy) with ipamorelin.

Typical research dose: Tesamorelin 1 mg + ipamorelin 200-300 mcg (clinic blend SKUs vary)

Reconstitution calculator ↓Tesamorelin online: Egrifta vs compounded cost →Sermorelin online: providers and cost →Telehealth clinics that prescribe peptides →

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Low

Typical research dose

Tesamorelin 1 mg + ipamorelin 200-300 mcg (clinic blend SKUs vary)

Frequency

1× daily (typically evening, empty stomach)

Half-life

~26–38 min + ~2 h

Common vials

5 mg / 10 mg

CAS

N/A (blend)

Molecular weight

Blend

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Metabolic / weight4/10
Tesamorelin VAT label is Egrifta, not this mix. Ipamorelin does not inherit that NDA.

Compound card

Class: Vendor mix (Egrifta analog class + ipamorelin)
Formula: Tesamorelin + ipamorelin
Status: Not FDA-approved · research use

Dose it

11 mg + 2 mL BAC water → 5.5 mg/mL · advertised cake. Confirm the COA, then use the blend calculator.

Open blend calculator

How it works

Tesamorelin is FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy, with visceral-fat data on label. Ipamorelin is a research GHRP. Clinic menus sell a single reconstituted vial. That is off-label for tesamorelin’s indication and unapproved as a combination product.

Source: Tesamorelin: FDA Egrifta label. Ipamorelin: see ipamorelin entry.

Research Use Cases

✓Visceral fat / GHRH: Moderate

Dosing

Phase	Dose	Frequency	Notes
Clinic blend (example)	Tesamorelin 1 mg + ipamorelin 200–300 mcg	Daily SC	Labeled tesamorelin monotherapy for lipodystrophy is 2 mg daily reconstituted with the kit diluent - do not assume the blend matches the PI.

Administration

Route / form

Subcutaneous

Timing

Often evening, empty stomach in clinic protocols.

Empty stomach?

Yes - Empty stomach (typical for this injectable class).

Timeline

Labeled tesamorelin (not the blend)

VAT reduction in HIV lipodystrophy trials over months.

Who it is for

Visceral fat / GHRH

Moderate

Tesamorelin has a label. The ipamorelin add-on does not.

Reconstitution

Vial	Water	Concentration	Example dose
11 mg lyophilized	2 mL BAC	5.5 mg/mL	Two peptides. Egrifta is 1 mg daily reconstituted from a labeled kit, not this cake.

Change vial size or water volume? Open the blend calculator.

Safety & Considerations

Tesamorelin is prescription. Glucose, IGF-1, injection-site reactions, and hypersensitivity are PI issues. Adding ipamorelin is off-label. WADA S2.

Regulatory & Legal Status

FDA Status (US)

Research Only

Tesamorelin (Egrifta®) is FDA-approved alone. The blend with ipamorelin is off-label / compounded

WADA Status (2026)

Prohibited (S2)

Competitive athletes subject to anti-doping controls should not use Tesamorelin + Ipamorelin.

Classification

Compounded Drug (Rx)

US Compounding: Available via licensed pharmacy Rx

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Do not print 15–18% VAT reduction on a blended research vial.

Verdict

Tesamorelin + ipamorelin is a clinic pairing. Egrifta VAT math stays on the tesamorelin leaf. The mix is not a second lipodystrophy drug.

Interactions & Contraindications

Tesamorelin is prescription. Glucose, IGF-1, injection-site reactions, and hypersensitivity are PI issues. Adding ipamorelin is off-label. WADA S2.

Frequently Asked Questions

Is this FDA-approved as a stack?▼

No. Tesamorelin is approved alone. Ipamorelin is not approved. The vial combo is compounding/clinic practice.

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library